Indication
Prevention of respiratory distress syndrome in the newborn
Respiratory distress syndrome in the newborn is an acute pulmonary disorder that predominantly affects premature neonates due to developmental deficiency of endogenous pulmonary surfactant and structural lung immaturity. Read more about Prevention of respiratory distress syndrome in the newborn
2 drugs 2 manufacturers
Drugs that treat it
Common Prevention of respiratory distress syndrome in the newborn therapies.
INFASURF (calfactant)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRespiratory distress syndrome in the newborn is an acute pulmonary disorder that predominantly affects premature neonates due to developmental deficiency of endogenous pulmonary surfactant and structural lung immaturity.
This surfactant deficiency increases alveolar surface tension, leading to widespread microatelectasis, ventilation-perfusion mismatch, reduced lung compliance, and progressive hypoxemia.
Clinically, affected neonates manifest symptoms shortly after birth, characterized by tachypnea, intercostal retractions, nasal flaring, audible expiratory grunting, and cyanosis.
Prophylactic management strategies focus on accelerating pulmonary maturation antenatally or replacing surfactant immediately postpartum to avert atelectasis and subsequent respiratory failure.
- nih.gov
Respiratory distress syndrome in the newborn is an acute pulmonary disorder that predominantly affects premature neonates due to developmental deficiency of endogenous pulmonary surfactant and structural lung immaturity This surfactant deficiency increases alveolar surface tension, leading to widespread microatelectasis, ventilation-perfusion mismatch, reduced lung compliance, and progressive hypoxemia Clinically, affected neonates manifest symptoms shortly after birth, characterized by tachypne...
- nih.gov
Respiratory distress syndrome in the newborn is an acute pulmonary disorder that predominantly affects premature neonates due to developmental deficiency of endogenous pulmonary surfactant and structural lung immaturity
- nih.gov
This surfactant deficiency increases alveolar surface tension, leading to widespread microatelectasis, ventilation-perfusion mismatch, reduced lung compliance, and progressive hypoxemia Prophylactic management strategies focus on accelerating pulmonary maturation antenatally or replacing surfactant immediately postpartum to avert atelectasis and subsequent respiratory failure
- aafp.org
Clinically, affected neonates manifest symptoms shortly after birth, characterized by tachypnea, intercostal retractions, nasal flaring, audible expiratory grunting, and cyanosis
- academyofneonatalnursing.org
Prophylactic management strategies focus on accelerating pulmonary maturation antenatally or replacing surfactant immediately postpartum to avert atelectasis and subsequent respiratory failure
Personalize your experience
Follow Prevention of respiratory distress syndrome in the newborn and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.